Introduction {#sec1-2045893217712710}
============

Adult-onset Still's disease (AOSD) is an inflammatory disorder characterized by recurrent fevers, arthralgia, leukocytosis, and a salmon-colored rash. Diagnosis is made based on the Yamaguchi criteria.^[@bibr1-2045893217712710]^ Various cardiac and pulmonary manifestations have been described in association with AOSD, including acute respiratory distress syndrome (ARDS) and pulmonary arterial hypertension (PAH).^[@bibr2-2045893217712710][@bibr3-2045893217712710][@bibr4-2045893217712710]--[@bibr5-2045893217712710]^ We present a case of a young woman who developed PAH and ARDS as a consequence of her AOSD, where her clinical course was initially concerning for pulmonary veno-occlusive disease (PVOD), which was ruled out on autopsy.

Case presentation {#sec2-2045893217712710}
=================

A 31-year-old African American woman presented with a two-week history of rapidly progressive shortness of breath on exertion and leg swelling. Prior to her presentation, she could complete activities of daily living without any difficulty but experienced dyspnea while climbing stairs and lifting heavy objects for the last year. Despite multiple hospitalizations for these issues at an outside community institution, an etiology for these symptoms was never fully evaluated or determined. The patient was diagnosed with AOSD at the age of 24 years and had previously been managed with various immunosuppressive therapies including prednisone and mycophenolate mofetil. Upon presentation to our institution, she was receiving prednisone and methotrexate for the management of her AOSD symptoms and was prescribed trimethoprim-sulfamethoxazole for prophylaxis. Physical examination was notable for hyperpigmented macules of the bilateral upper arms, lower extremity pitting edema, distended jugular venous pulse with accentuated hepatojugular reflex, and a loud P2 on cardiac auscultation.

Her chest radiograph (CXR) is shown in [Fig. 1](#fig1-2045893217712710){ref-type="fig"}. A transthoracic echocardiogram showed normal left ventricular size and function with an ejection fraction of 55--60%, severe enlargement of the right ventricle and atrium, flattening of the interventricular septum in systole and diastole, and severe tricuspid regurgitation ([Fig. 2](#fig2-2045893217712710){ref-type="fig"}). Right ventricular systolic pressure was estimated at 70--80 mmHg and there was evidence of a small pericardial effusion. A non-contrasted CT of the chest on admission revealed extensive mediastinal and hilar lymphadenopathy with some axillary lymphadenopathy, an enlarged pulmonary artery of approximately 39 mm, and extensive mosaic attenuation throughout the bilateral lungs ([Fig. 3](#fig3-2045893217712710){ref-type="fig"}) with no evidence of pulmonary embolism. Fig. 1CXR on day of admission showing clear lung fields, cardiomegaly, and a slightly widened mediastinum. Fig. 2Apical four-chamber view showing right atrial and ventricle dilation and a small pericardial effusion. Fig. 3Chest CT without contrast performed on day of admission showing evidence of mild bilateral mosaic attenuation throughout the lungs.

The patient was clinically fluid overloaded on presentation (elevated jugular venous pulsation, bilateral lower extremity edema) requiring diuresis to optimize her fluid status prior to right heart catheterization (RHC). Laboratory evaluation revealed an elevated NT-pro-BNP of 1566 pg/mL, transaminitis (AST and ALT were 790 and 697 U/L, respectively, total bilirubin 1.0 mg/dL and alkaline phosphatase 81 U/L), elevated C-reactive protein (105.2 mg/L), and a leukocytosis (16.9 thou/cu mm with 90% PMNs). The patient's transaminitis was new when compared with values from a few months prior. An ANA titer was positive at 1:160; however, the rest of her autoimmune workup and HIV status were negative. Right upper quadrant ultrasound showed mild hepatomegaly without cirrhosis consistent with hepatic congestion. Her RHC findings were consistent with pre-capillary PAH. Pulmonary artery pressures were measured to be 52/30 mmHg with a mean of 38 mmHg. Her pulmonary artery occlusion pressure was normal at 8 mmHg ([Table 1](#table1-2045893217712710){ref-type="table"}). Given that the patient was functional class IV and had a high-risk hemodynamic pulmonary profile according to 2015 ESC/ERS guidelines for the diagnosis of pulmonary hypertension,^[@bibr6-2045893217712710]^ given the high right atrial pressure, low cardiac index, and low mixed venous oxygen saturation, she was initiated on intravenous epoprostenol and oral tadalafil, with plans to add an endothelial receptor blocker as a third agent. Additionally, as she continued diuresis, she experienced hypotension with systolic pressures as low as 70 mmHg with a lactic acidosis as high as 4.9 mmol/L (which later resolved with the addition of a dobutamine infusion). Table 1Right heart catheterization.MeasurementValueRight atrium23 mmHgRight ventricle50/21 mmHgPulmonary artery52/30 mmHgMean pulmonary artery pressure38 mmHgPulmonary artery occlusion pressure8 mmHgCardiac output (thermodilution)2.9 L/minCardiac index (thermodilution)1.6 L/min/m^2^Pulmonary vascular resistance10.3 Woods UnitsPulmonary arterial oxygen saturation97%Pulmonary venous oxygen saturation40%Hemoglobin9.5 g/dL

Over the subsequent three days, the patient began to decline, exhibiting symptoms of right ventricular failure. Inhaled epoprostenol at 50 ng/kg/min was initiated and epoprostenol infusion was gradually increased to a rate of 8 ng/kg/min. Despite this, she exhibited worsening hypoxia on serial arterial blood gas measurements despite increasing her inhaled FiO2. Due to her hemodynamic instability, the patient was worked up for an infectious etiology and broad-spectrum antimicrobial coverage was initiated.

Despite these interventions, the patient continued to deteriorate. She ultimately required endotracheal intubation and mechanical ventilation due to her worsening hypoxia (desaturations as low as 70% on 100% inhaled FiO2 non-rebreather mask) in conjunction with tachycardia to 160 beats per minute. Her lactic acidosis returned as well, peaking at 3.6 mmol/L. Complete blood count revealed a worsening leukocytosis 24.9 thou/cu mm with 15% bands. The patient's CXR prior to intubation ([Fig. 4](#fig4-2045893217712710){ref-type="fig"}) and clinical picture at the time of this decompensation was consistent with ARDS. Shortly after intubation, the patient experienced pulseless electrical activity and despite advanced cardiovascular life support she ultimately died. The rapid decline after initiating pulmonary arterial hypertension therapy was concerning for possible underlying pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemagiomatosis (PCH). Additionally, her rapid decline precluded the possibility of any repeat imaging or advanced monitoring of cardiac output. Fig. 4CXR three days after admission revealing diffuse bilateral infiltrates.

Autopsy revealed right ventricular hypertrophy and moderately dilated right ventricle and right atrium. Additionally, the patient's lungs were significant for diffuse alveolar damage with prominent hyaline membrane formation with edema and a prominent neutrophilic alveolar infiltrate. There was both intimal thickening of the pulmonary arteries and arterioles ([Fig. 5](#fig5-2045893217712710){ref-type="fig"}). Features suggestive of the presence of PVOD and PCH were not present on pathological examination. Pathology slides were sent out for a second opinion that confirmed the initial report. Regardless, all cultures and staining performed on lung samples did not identify any infectious organisms. The final diagnosis was PAH and ARDS in the setting of AOSD. Considering the right ventricular hypertrophy present on autopsy and her report of dyspnea on exertion for the year prior to her decompensation, it is likely the patient's PAH had been present for some time and not recognized during her previous hospitalizations. Fig. 5Pulmonary histology showing evidence of pulmonary arteriole intimal thickening (blue arrow) and hypertrophy as well as prominent alveolar edema and neutrophilic alveolar infiltrate (red arrow).

Discussion {#sec3-2045893217712710}
==========

AOSD is a rare systemic autoinflammatory disease whose prevalence is roughly 0.16/100,000.^[@bibr7-2045893217712710]^ The disease usually presents in young individuals, but there is a degree of bimodality to the age distribution.^[@bibr8-2045893217712710],[@bibr9-2045893217712710]^ AOSD with PAH typically occurs in young women and to date 12 cases have been published ([Table 2](#table2-2045893217712710){ref-type="table"}). Table 2Cases of AOSD and PAH.AuthorsAgeSexFeverWBC (thou/mm^3^)ArthralgiaRashTherapy for PH/AOSDOutcomeZen et al., 1990^[@bibr18-2045893217712710]^29F+Elevated++None/noneDiedChen et al., 2006^[@bibr19-2045893217712710]^41FNANANANANone/noneSurvivedChen et al., 2006^[@bibr19-2045893217712710]^27FNANANANANone/noneSurvivedMubashir et al., 2007^[@bibr20-2045893217712710]^29F+Elevated++Nifedipine 60 mg daily/ corticosteroids, anakinraDiedde Siqueira et al., 2009^[@bibr21-2045893217712710]^18F+32.6++None/indomethacin, corticosteroids, methotrexateSurvivedKhattri et al., 2011^[@bibr22-2045893217712710]^26F+16.3 (87% PMNs)++None/corticosteroids, naproxenSurvivedCampos et al., 2012^[@bibr12-2045893217712710]^27F+Elevated++Amlodipine/corticosteroids, azathioprine, anakinraSurvivedIbarra et al., 2013^[@bibr23-2045893217712710]^43F−11.8−+Sildenafil/corticosteroids, cyclophosphamide, rituximabSurvivedThakare et al., 2013^[@bibr5-2045893217712710]^18F+23.2−+None/noneNAKadavath et al., 2014^[@bibr24-2045893217712710]^38F+27.1++None/corticosteroids, toclizumabSurvivedGuilleminault et al., 2016^[@bibr3-2045893217712710]^19F+"Normal"++Ambrisentan, tadalafil/ corticosteroids, methotrexate, anakinraDiedWong et al., 2016^[@bibr13-2045893217712710]^24F+NA++Epoprostenol, tadalafil, treprostinil, ambrisentan, tadalafil/corticosteroids, methotrexateSurvivedOur case31F+16.9 (90% PMNs)++Epoprostenol, tadalafil/ corticosteroids, methotrexateDied[^1]

Although the mortality in AOSD is low,^[@bibr10-2045893217712710]^ it increases dramatically in cases where the disease is complicated by cardiopulmonary abnormalities.^[@bibr11-2045893217712710]^ PAH and ARDS are rare complications of AOSD. We report the first case where both complications occurred in a patient with AOSD. The presence of mediastinal adenopathy on chest imaging and the patient's clinical decline after initiation of PAH-specific therapy was concerning for PVOD/PCH. However, autopsy failed to show evidence suggestive of either. To date, there have been no cases of PVOD/PCH reported in association with AOSD.

The exact pathophysiology of AOSD is unknown, but much of the disease seems to involve macrophage and neutrophil activation. Furthermore, therapy for AOSD can involve inhibition of IL-1, IL-18, and TNFα, implicating their role in the disease.^[@bibr12-2045893217712710][@bibr13-2045893217712710]--[@bibr14-2045893217712710]^ With regards to PAH, there is a consensus that dysregulation of these cytokines plays a role in the remodeling of the pulmonary vasculature via recruiting of inflammatory cells. It seems reasonable to conclude that this similarity between AOSD and PAH could represent a reasonable mechanism for the pathophysiology of the disease; however, more research is necessary.

The mainstay of treatment of AOSD involves immunosuppression. Specifically, inhibition of IL-1 with anakinra has been associated with improved outcomes in AOSD and PAH.^[@bibr12-2045893217712710],[@bibr14-2045893217712710]^ In this case, the patient was continued on her prior immunosuppressive regimen for AOSD. Escalation of her immunosuppressive therapy was considered; however, due to her rapid hemodynamic decline and the possibility of an infectious etiology, we decided the benefit did not outweigh the risk at that time. Furthermore, the choice was made to prioritize treatment of the patient's right-sided heart failure as a consequence of her PAH given her rapidly progressing hemodynamic instability and eventual hypoxic respiratory failure.

AOSD does have an established relationship with ARDS ([Table 3](#table3-2045893217712710){ref-type="table"}), having now been published in 18 cases. ARDS is known to occur because of the pathogenic production of cytokines, such as TNFα and IL-1.^[@bibr15-2045893217712710][@bibr16-2045893217712710]--[@bibr17-2045893217712710]^ This has been established in the context of sepsis, but as previously mentioned, these cytokines are implicated in the development of PAH from AOSD. It stands to reason that the pathogenic release of these cytokines from AOSD could also result in ARDS and PAH, such as in this case. Table 3Cases of AOSD and ARDS.AuthorsAge, yearsSexFeverWBC (thou/mm^3^)ArthralgiaRashTherapy for AOSDOutcomeHirohata et al., 1986^[@bibr4-2045893217712710]^65F+14+−Corticosteroids, cyclophosphamideDiedPederson et al., 1991^[@bibr25-2045893217712710]^40M+33++Corticosteroids, azathioprineSurvivedGibbs et al., 1993^[@bibr26-2045893217712710]^21F+NA+−CorticosteroidsSurvivedYokoyama et al., 1995^[@bibr27-2045893217712710]^71M+NA−+Corticosteroids, nafamostat mesilateSurvivedIglesias et al., 1999^[@bibr28-2045893217712710]^29F+16.6+−CorticosteroidsSurvivedShinohara et al., 1999^[@bibr29-2045893217712710]^54F+17.7 (84% PMNs)++CorticosteroidsSurvivedMito et al., 2002^[@bibr30-2045893217712710]^24F+NA−+Corticosteroids, cyclosporineSurvivedSuleiman et al., 2002^[@bibr31-2045893217712710]^36F+30.9−−Corticosteroids, methotrexateSurvivedHagiyama et al., 2003^[@bibr32-2045893217712710]^24F+12.9 (95% PMNs)−−Corticosteroids, cyclophosphamideSurvivedHagiyama et al., 2003^[@bibr32-2045893217712710]^20M+12.2 (88% pmns)−+CorticosteroidsSurvivedManganelli et al., 2003^[@bibr33-2045893217712710]^17F+NA−+Corticosteroids, 6-mercaptopurine, cyclosporine, IVIGDiedBiron et al., 2006^[@bibr34-2045893217712710]^39F+22 (90% PMNs)++CorticosteroidsSurvivedBiron et al., 2006^[@bibr34-2045893217712710]^68F+28 (88% PMNs)++CorticosteroidsSurvivedBiron et al., 2006^[@bibr34-2045893217712710]^43M+15.6 (91% PMNs)−−Corticosteroids, IVIGSurvivedGuignard et al., 2007^[@bibr14-2045893217712710]^23M+21−+Corticosteroids, methotrexateSurvivedChvojka et al., 2009^[@bibr35-2045893217712710]^24M+NA−−CorticosteroidsDiedDua et al., 2013^[@bibr2-2045893217712710]^26F+20 (92% PMNs)−−CorticosteroidsDiedOur case, 201631F+16.9 (90% PMNs)++Corticosteroids, methotrexateDied[^2]

What is not clear is why, exactly, ARDS and PAH tends to be so fulminant in cases of AOSD. It has been noted that any pulmonary complication has been associated with a poorer outcome and our patient experienced two concomitant severe pulmonary complications.^[@bibr11-2045893217712710]^ Considering the pathophysiology of extremely rapid decline is unclear, it perhaps highlights avenues for further research to elucidate a mechanism beyond that of the release of cytokines.

As in our case, patients with AOSD are frequently empirically treated with broad-spectrum antimicrobial therapy, but tend to ultimately be transitioned to aggressive immunosuppression. Our case differs in that the patient's clinical status was more fulminant given her severe right heart failure due to PAH. This precluded the possibility of definitively excluding infectious etiologies and allowing for adequate and timely treatment with immunosuppression.

Conclusion {#sec4-2045893217712710}
==========

We describe the first case of both PAH and ARDS in a patient with AOSD who, despite aggressive therapy, declined rapidly and ultimately died. Treatment of AOSD with cardiopulmonary involvement requires rapid identification of AOSD as the etiology for decompensation followed by aggressive immunosuppression. Considering this, we recommend early involvement of rheumatology specialists in cases where patients present with new onset respiratory failure with a history of rheumatologic disease in which pulmonary hypertension is in the differential diagnosis. This case also highlights how the concomitant presentation of these two conditions may be mimicking the clinical presentation of PVOD or PCH. No standard of care for the management of these conditions currently exist.
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[^1]: F, female; +, present; −, not present; NA, not available.

[^2]: F, female; M, male; +, present; −, not present; NA, not available.
